Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, International Stem Cell's enterprise value is $5.17 Mil.
International Stem Cell's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.27 Mil. Therefore, International Stem Cell's EV-to-EBITDA for today is -19.16.
The historical rank and industry rank for International Stem Cell's EV-to-EBITDA or its related term are showing as below:
ISCO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -844.81 Med: -2.65 Max: 248.13
Current: -19.16
During the past 13 years, the highest EV-to-EBITDA of International Stem Cell was 248.13. The lowest was -844.81. And the median was -2.65.
ISCO's EV-to-EBITDA is ranked worse than 100% of 414
companies
in the Biotechnology industry
Industry Median: 13.55
vs ISCO: -19.16
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
International Stem Cell (OTCPK:ISCO) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
International Stem Cell's PE Ratio (TTM) for today is calculated as:
International Stem Cell's share price for today is $0.35.
International Stem Cell's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.080.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, International Stem Cell's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
International Stem Cell EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, International Stem Cell's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where International Stem Cell's EV-to-EBITDA falls into.
International Stem Cell's current Enterprise Value is $5.17 Mil.
International Stem Cell's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
International Stem Cell (ISCO) has a EV-to-EBITDA of -19.16 as of Aug. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on International Stem Cell. According to the industry distribution chart, International Stem Cell ranks #999999 out of 414 companies in the Biotechnology industry.
Is International Stem Cell's EV-to-EBITDA too high?
International Stem Cell's current EV-to-EBITDA is -19.16. Based on the distribution chart, International Stem Cell ranks #999999 out of 414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, International Stem Cell has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does International Stem Cell's EV-to-EBITDA compare to GRI and VRAX?
According to the Biotechnology industry distribution chart, International Stem Cell ranks #999999 out of 414 companies for EV-to-EBITDA. This places International Stem Cell in the lower half of its industry. The industry median EV-to-EBITDA is 13.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.55, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on International Stem Cell. For the Biotechnology industry, the median EV-to-EBITDA is 13.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. International Stem Cell's current EV-to-EBITDA is -19.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Stem Cell stock overvalued right now?
Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.35 — trading 169.2% above its estimated fair value. The current EV-to-EBITDA is -19.16. International Stem Cell's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For International Stem Cell (ISCO), the current EV-to-EBITDA is -19.16 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is International Stem Cell (ISCO) Overvalued in 2026?
Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued.
The current stock price of $0.35 is trading 169.2% above its estimated GF Value™ of $0.13.
GuruFocus considers International Stem Cell to be Significantly Overvalued.
Key valuation signals for ISCO:
EV-to-EBITDA: -19.16
GF Value™: $0.13 vs. price of $0.35 (169.2% above fair value)
No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
20GF Score
Get the complete analysis for ISCO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISCO has been successfully added to your 
